Cargando…
TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
BACKGROUND: Patients with diabesity have a significantly increased risk of developing cardiovascular disease. Therefore, therapy addressing the multiple metabolic abnormalities linked with diabesity and leading to further reduction of cardiovascular risk is highly desirable. Activation of the TGR5 r...
Autores principales: | Zambad, Shitalkumar P, Tuli, Davinder, Mathur, Anoop, Ghalsasi, Sameer A, Chaudhary, Anita R, Deshpande, Shailesh, Gupta, Ramesh C, Chauthaiwale, Vijay, Dutt, Chaitanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873233/ https://www.ncbi.nlm.nih.gov/pubmed/24379686 http://dx.doi.org/10.2147/DMSO.S50209 |
Ejemplares similares
-
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis
por: Gupta, Ram, et al.
Publicado: (2014) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Zambad, Shitalkumar P, et al.
Publicado: (2011) -
TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats
por: Mohanan, Anookh, et al.
Publicado: (2011) -
TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007) -
Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
por: Rossi, Edoardo, et al.
Publicado: (2021)